Latest news for Flowerkist Skin Care (OTC:FKST) Stock

Flowerkist Skin Care & Cosmetics Inc is involved in developing and contract manufacturing CBD-infused skincare and cosmetics. Marketing and selling these products through various online and targeted channels including Medical SPAs.

FLOWERKIST SKIN CARE CSMT by Flowerkist Skin Care & Cosmetics, Inc.

Flowerkist Skin Care & Cosmetics Inc

IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (ACN 629 842 799) ("IREN") today announced its intention to offer, subject to market and other conditions, $300&nbsp;million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). IREN also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45&nbsp;million principal amount of notes.
The notes will be senior, unsecured obligations of IREN, will accrue interest payable semi-annually in arrears and will mature on June 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. IREN will settle conversions by paying or delivering, as the case may be, cash, its ordinary shares or a combination of cash and its ordinary shares, at its election.

News

Offerings

IREN

IREN Announces Its Intention To Offer $300M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

WIIM

BASE

Couchbase shares are trading lower after the company issued Q4 revenue guidance below estimates.

Insider Trades

Goldman Sachs CEO David Solomon Sells 6,550 Shares For ~$4M At $610.91 Each, Retains 117,883 Shares Directly And 16,171 Indirectly Through Family Trust

Salesforce shares are trading higher after the company reported Q3 earnings and raised its guidance.

<a href="https://www.globenewswire.com/Tracker?data=8Tf7Z3_YTnk-drIFCyK3YwK5fBKtJERg8a5F3K8syiG68jnjCZnBJKIYCATZd01jimcmqpP1528lJYHqXWY-ma414azilZr-CI5Zg79wOZw=">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, <a href="https://www.globenewswire.com/Tracker?data=0eWtnXxZi0DLMosegLjoiOoxfutWhH7qSlf7dqC2xfyHNQu-tfX-H-3N7YMQ4Mml7pdz18Wt2RW-5K2mAnTcbFd--zxV1VGeBPo_CnnN2LU=">click here</a>.
Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF).
The event will focus on Tectonic's lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study.
A live question and answer session will follow the formal presentations.

Biotech

General

TECX

Tectonic Therapeutic To Host KOL Event On The Unmet Need In Group 2 PH-HFpEF And TX45 As A Potential Treatment On Thursday, December 12, 2024 From 4:00 PM To 6:00 PM ET

The partnership also includes the successful demonstration of Parsons' software-defined satellite communications solution using Globalstar's Low Earth Orbit (LEO) satellite constellation.

Contracts

GSAT

Parsons, Globalstar Enter Exclusive Partnership To Support The Public, Government, And Defense Sectors

Guidance

CURV

Torrid Holdings Sees FY24 Revenue $1.083B-$1.098B Vs $1.139B Est.

PSTG

Public Storage shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

Salesforce Raises Full Year FY25 GAAP Operating Margin Guidance To 19.8% And Raises non-GAAP Operating Margin Guidance to 32.9%

Salesforce Raises Low End Of Full Year FY25 Revenue Guidance to $37.8B-$38.0B, Up 8%- 9% Y/Y

&nbsp;8.4 EH/s Capacity Achieved With 68% YoY Growth, $41K Power Cost Per Bitcoin, And 7,400 S21 Pro Miners Installed

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

WULF

TeraWulf Reports November 2024 Update Of 115 Bitcoin Mined

Salesforce shares are trading higher after the company reported better-than-expected Q3 sales results.

Couchbase Tightens FY25 Total Revenue Outlook From $205.1M - $209.1M To $207.2M - $208.0M, Est $207.658M

Full-Year Fiscal 2025 Guidance: Based on the company's first quarter performance, Campbell's is re-affirming its full-year fiscal 2025 guidance provided on August 29, 2024. Guidance ranges reflect a balance between expected sequential progress and pragmatism as the company continues to navigate the dynamic consumer environment and uneven category recovery. The upper end of the range anticipates a quicker normalization of the consumer environment while the lower end of the range assumes a slower, more conservative pace of recovery.

The Campbell's Company Says Based On The Company's Q1 Performance, Campbell's Is Re-Affirming Its FY25 Guidance Provided On August 29, 2024

MRVL

Marvell Technology shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

The Q3 earnings report for Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) was released on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Couchbase beat estimated earnings by 38.0%, reporting an EPS of $-0.05 versus an estimate of $-0.08.
Revenue was up $5.82 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.03 in the previous quarter, leading to a 15.0% drop share price change the next day.
Here's a look at Couchbase's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.15</td>
<td>-0.14</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.10</td>
<td>-0.06</td>
<td>-0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>51.08M</td>
<td>48.56M</td>
<td>46.56M</td>
<td>43.10M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>51.59M</td>
<td>51.33M</td>
<td>50.09M</td>
<td>45.81M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Couchbase <a href="https://www.benzinga.com/quote/BASE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights into Couchbase Q3 Earnings

Quarterly Dividend Increase The company's Board of Directors has approved an increase in its quarterly dividend from $0.37 per share to $0.39 per share, an increase of 5%, or $1.56 on an annualized basis. The quarterly dividend is payable on January 27, 2025, to shareholders of record at the close of business January 2, 2025.
 &nbsp;

Dividends

The Campbell's Company Increases Quarterly Dividend From $0.37 To $0.39 Per Share

LUNR

Intuitive Machines Launches $65M Public Offering Of Class A Common Stock Alongside $10M Private Placement With Boryung Corporation

XAIR

Beyond Cancer Secures Approval From Israeli Ministry Of Health For Phase 1b Trial Combining Low Volume Ultra-High Concentration Nitric Oxide With Anti-PD-1 Therapy In Solid Tumor Patients

NOTV

Inotiv Q4 2024 Adj. EPS $(0.73) Down From $(0.38) YoY, Sales $130.417M Down From $140.740M YoY

Flowerkist Skin Care

Comments

Flowerkist Skin Care

News

Latest news for Flowerkist Skin Care (OTC:FKST) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga